Table 5 EWAS DMPs identified in treatment responders vs. non responders at T2 (post-treatment), and T3 (follow-up).

From: Distinct saliva DNA methylation profiles in relation to treatment outcome in youth with posttraumatic stress disorder

Responders vs Non Responders T2

Probe

Chr

Position

FDR

DeltaBeta

Gene

Gene Feature

cg24809382

15

55582033

0.99

0.0076

RAB27A

TSS1500

cg17251423

5

139088815

0.99

−0.1560

CTB-35F21.1

Body

cg08273874

16

1060765

0.99

0.0554

 

-

cg00313642

3

196014711

0.99

0.0414

PCYT1A

Body

cg08313638

10

12110577

0.99

−0.0443

DHTKD1

body

Responders vs Non Responders T3

cg15154763

18

71982463

0.05**

0.2259

C18orf63

TSS1500

cg11198041

14

35344866

0.83

0.0801

BAZ1A

TSS200

cg17700633

19

13263997

0.83

−0.0246

IER2

5’UTR

cg07275860

12

120554537

0.83

0.0521

RAB35

5’UTR

cg14362428

6

31116408

0.83

−0.0751

CCHCR1

Body

  1. Top 5: EWAS DMPs from our cross sectional analysis between treatment responders vs. non responders at T2 (post-treatment), and T3 (follow-up). DMPs: Differently methylated positions. Genome build (HG19 chr: chromosome; FDR: false discovery rate based on bacon adjusted p-value (Mval); DeltaBeta: delta differences between groups, based on average β-value; Gene: UCSC Reference Gene Name; Gene feature: gene feature according Illumina manifest **indicates a epi-genome wide significant result.
Back to article page